drugset / Trial / NCT06396858
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Phase 4
Not yet recruiting
4500 enrolled
Brazilian Clinical Research Institute
Alliança Diagnostic · collab
RandomizedFactorialQuadruple-blindPrevention
Summary
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.
Timeline
- Start
- 2026-07
- Primary completion
- 2027-08
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.5 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 2.5 mg | Oral |